Previously, Axonis raised $34+M in dilutive Seed funding and $8+M in competitive non-dilutive grants/awards. First-in-human trials began in 2024 for the first-in-class oral KCC2 potentiator …

Axonis’ lead candidate AXN-027 is a first- and best-in-class oral KCC2-potentiating drug currently being evaluated in a Phase 1 clinical trial, and is being developed for the treatment of …

“Axonis’ vision is to advance a pipeline of oral KCC2 therapeutics to restore functional inhibition in the CNS to treat neurological disorders without disabling side effects,” said Joanna Stanicka, …

Oct 8, 2020 · Axonis Therapeutics, Inc. Announces Seed Financing May 28: AXONIS Therapeutics, Inc. announces the close of the first tranche of a $4 million Seed Preferred …

Learn more about Axonis' scientific approach to combat patients' drug-resistance or disabling side effects of these first-line medications

At Axonis, we are advancing a first- and best-in-class oral KCC2-potentiating small molecule into the clinic. Fine-tuning chloride homeostasis in CNS neurons will enable them to respond to …

Axonis Therapeutics is advancing breakthrough drug discoveries to develop first-in-class therapies for currently incurable neurological disorders, in order to make a real difference for …

Axonis Therapeutics is advancing breakthrough drug discoveries to develop first-in-class therapies for currently incurable neurological disorders, in order to make a real difference for …

Joanna Stanicka, Ph.D., is scientific co-founder, IP inventor and CEO of Axonis Therapeutics, Inc., a pioneering biotech company developing first-in-class therapies to treat unmet …

Dr Shane Hegarty is Chief Scientific Officer, Co-Founder and IP Co-Inventor at AXONIS Therapeutics, a Boston-based biotechnology company. He has 15+ years of experience …